Testing Rapid Assays for p53 Mutations in Cancer Families
Author Information
Author(s): Camplejohn R S, Sodha N, Gilchrist R, Lomax M E, Duddy P M, Miner C, Alarcon-Gonzalez P, Barnes D M, Eeles R A
Primary Institution: Richard Dimbleby Department of Cancer Research, Guy's, Kings and St Thomas' Medical School, St Thomas' Hospital, London, SE1 7EH, UK
Hypothesis
Can rapid functional assays effectively detect germline p53 mutations in Li-Fraumeni and Li-Fraumeni-like families?
Conclusion
The study found that rapid functional assays for p53 mutations show good agreement with direct sequencing and are effective for initial screening.
Supporting Evidence
- The apoptotic assay is rapid, inexpensive, and simple to perform.
- The FASAY detects mutations in exons 4–10 and distinguishes between functionally important and silent mutations.
- No false-positives or negatives were seen with either functional assay.
Takeaway
Scientists tested quick methods to check for gene problems in families with certain cancer risks, and they worked well.
Methodology
Two rapid assays (apoptotic assay and FASAY) were compared with direct sequencing of the p53 gene.
Limitations
The apoptotic assay had one borderline result, and the FASAY only detects mutations in specific exons.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website